(thirdQuint)Safety and Efficacy of Ad-p53 in Head and Neck Cancer.

 This is a Phase 2 study of the combination of Ad-p53 administered intra-tumorally in combination with Opdivo infusions in patients with recurrent head and neck squamous cell cancer and favorable p53 status.

 This safety and efficacy study has two unblinded cohorts, Arm A will be treated with the combination of Ad-p53 and Opdivo, while Arm B is treated solely with Opdivo.

 Randomization will be done to ensure equal numbers in each arm.

 Patients will be followed for adverse events, ECOG status and preliminary efficacy.

 General safety and preliminary efficacy will be determined using RECIST 1.

1, ECOG status and, as indicated, Immune-Related Response Criteria.

 Biomarker testing of archival or fresh tissue is performed during the study.

 Patients will undergo a maximum of 3 28-day cycles, with scans every 8 weeks.

 No additional biopsies will be required after Screening.

 Enrollment will be up to 40 patients.

.

 Safety and Efficacy of Ad-p53 in Head and Neck Cancer@highlight

This is a Phase 2 study of the combination of Ad-p53 administered intra-tumorally with Nivolumab in patients with recurrent head and neck squamous cell cancer and favorable p53 status.

 There are two cohorts, one with Ad-p53 in combination with Opdivo, one with Opdivo alone, in an unblinded design.

 General safety and efficacy using RECIST 1.

1 and Immune-Related Response Criteria as well as ECOG numbers will be followed.

